Study guide
4.2 Deemed Accreditation Organizations (CAP, The Joint Commission, COLA, ISO 15189)
Diplomate in Laboratory Management ASCP DLM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: DLM Credential Overview & Exam Strategy
1.1 DLM Exam Structure, Computer-Adaptive Delivery & Scoring 1.2 Eligibility Routes, Preparation Strategy & Credential Maintenance
2 Chapter 2: Quality Assurance & Analytical Performance
2.1 Statistical Quality Control, Levey-Jennings Charts & Westgard Multirules 2.2 Individualized Quality Control Plans, Risk Assessment & CLSI EP23 2.3 Method Verification, Validation Protocols & CLSI Standards
3 Chapter 3: Quality Systems, Auditing & Continuous Improvement
3.1 Nonconforming Event Management, Root Cause Analysis & CAPA Systems 3.2 Quality Auditing, Tracer Methodology & Document Control Systems 3.3 Lean Principles, Six Sigma Metrics & Laboratory Process Improvement (DMAIC)
4 Chapter 4: Regulatory Compliance & Accreditation Standards
4.1 CLIA '88 Regulations, Test Complexity Categorization & CMS Licensure 4.2 Deemed Accreditation Organizations (CAP, The Joint Commission, COLA, ISO 15189)
5 Chapter 5: Laboratory Cost Accounting & Financial Fundamentals
5.1 Financial Statements, Accounting Principles & Ratio Analysis in Clinical Labs 5.2 Cost Accounting, Cost-Per-Test Calculations & Break-Even Volume Analysis 5.3 Cash Flow Management, Working Capital & Variance Tracking
6 Chapter 6: Budgeting & Capital Equipment Planning
6.1 Operating Budget Development (Incremental vs. Zero-Based) & Monthly Variance Analysis 6.2 Capital Equipment Acquisition, Net Present Value (NPV), Payback Period & Depreciation 6.3 Vendor Contract Negotiations, Lease Options & Reagent Rental Agreements
7 Chapter 7: Reimbursement, Revenue Cycle & Resource Utilization
7.1 Revenue Cycle Management, Medical Necessity & Coding (CPT, HCPCS, ICD-10-CM) 7.2 Healthcare Reimbursement Models, Clinical Lab Fee Schedule (CLFS) & PAMA 7.3 Laboratory Utilization Management, Diagnostic Stewardship & Test Menu Rationalization 7.4 Materials Management, Inventory Control, Economic Order Quantity & JIT Delivery
8 Chapter 8: Organizational Design, Staffing & Compensation
8.1 Organizational Structure, Leadership Models & Standardized Job Descriptions 8.2 Workload Measurement Systems, FTE Calculations & Staff Scheduling 8.3 Wage and Salary Administration, Market Benchmarking & Total Compensation Design
9 Chapter 9: Talent Acquisition, Retention & Performance
9.1 Recruitment Strategies, Behavioral Interviewing & Legal Separation Protocols 9.2 Employee Onboarding, Training & CLIA '88 Six-Element Competency Assessment 9.3 Performance Management Systems, Annual Reviews & Performance Improvement Plans (PIPs)
10 Chapter 10: Workplace Culture, Relations & Legal Compliance
10.1 Staff Engagement, Retention Strategies & Workplace Recognition Programs 10.2 Conflict Resolution Strategies, Negotiation Tactics & Labor Relations 10.3 Employment Law & Human Resources Compliance (FLSA, FMLA, ADA, EEOC, OSHA)
11 Chapter 11: Strategic Operations, Facilities & Equipment Management
11.1 Strategic Planning, Mission Alignment, Environmental Scanning & SWOT Analysis 11.2 Clinical Laboratory Facility Design, Biosafety Layouts & Ergonomics 11.3 Equipment Lifecycle Management, Preventive Maintenance & Vendor Service Agreements
12 Chapter 12: Laboratory Safety, Biosafety & Emergency Preparedness
12.1 Comprehensive Laboratory Safety Programs (OSHA, Chemical Hygiene, CLSI QMS28) 12.2 Hazardous Chemical and Biohazard Waste Management & Exposure Control Plans 12.3 Disaster Preparedness, Business Continuity & Emergency Operations Planning
13 Chapter 13: Laboratory Informatics, Outreach & Project Leadership
13.1 Laboratory Information Systems (LIS), Middleware & HL7/FHIR Interfaces 13.2 Clinical Data Analytics, LIS Validation, Cybersecurity & HIPAA Protection 13.3 Project Management Frameworks (Agile, Waterfall) & Clinical Implementation Lifecycles 13.4 Outreach Business Operations & Multidisciplinary Clinical Care Teams
4.2 Deemed Accreditation Organizations (CAP, The Joint Commission, COLA, ISO 15189)
Key Takeaways Explain This Topic AI
CMS may recognize an accreditation organization whose requirements meet or exceed CLIA, but CMS retains oversight through validation and complaint surveys.
CAP uses peer inspection on a two-year cycle; U.S. and Canadian laboratories generally receive no more than 14 calendar days’ notice and conduct a self-inspection in the intervening year.
CAP deficiency responses are due within 30 calendar days; Phase II responses require supporting evidence, while the checklist item determines the phase.
For regulated analytes, CLIA PT generally uses three events per year and laboratories test PT samples like patient specimens without interlaboratory communication before the reporting deadline.
Unsuccessful PT performance requires investigation and correction, but CMS enforcement is case-specific; current guidance does not impose one automatic six-month cessation rule for every initial unsuccessful event.
Last updated: September 2026
- Deemed Accreditation Organizations and Proficiency Testing
- CLIA deeming authority
CMS may approve a private accreditation organization when its requirements and enforcement are equal to or more stringent than CLIA. A laboratory accredited by an approved organization receives a Certificate of Accreditation from CMS and is ordinarily surveyed by that organization instead of the State Survey Agency. Deemed status does not eliminate federal oversight. CMS or a State Survey Agency may conduct validation or complaint surveys and may act on condition-level noncompliance.
Laboratory leaders should distinguish four sources of requirements: federal CLIA law and regulation; CMS interpretive guidance and survey procedures; the chosen accreditor's current standards and checklist; and state or local rules that may be more stringent. When sources differ, comply with every applicable requirement.
Comparing accreditation approaches
Program Characteristic approach Management focus
CAP Laboratory Accreditation Program Peer inspection with detailed laboratory and discipline checklists Evidence that each checklist requirement is implemented and effective
The Joint Commission laboratory program Tracer-oriented review integrated with patient-care systems Handoffs, identification, communication, and system-level risk
COLA Survey and education oriented toward laboratories including physician-office settings Sustainable compliance and corrective improvement
AABB Specialized standards for blood, transfusion, cellular therapy, and biotherapies Donor/recipient safety, traceability, and product controls
ISO 15189 accreditation Process and competence assessment against an international QMS standard Risk, impartiality, competence, audit, and continual improvement
ISO 15189 is a standard; the actual accrediting body and scope must be identified rather than treating “ISO” as a regulator.
CAP inspection cycle and preparation
CAP-accredited laboratories are inspected on a two-year cycle. CAP states that laboratories in the United States and Canada receive no more than 14 calendar days' notice of an inspection. During the intervening year the laboratory completes a self-inspection using the current checklists. Inspection timing or notice outside those jurisdictions may differ, so managers follow current CAP instructions.
Readiness is continuous. A useful evidence chain for any checklist item is a current approved procedure, routine performance records, competency or training evidence where relevant, review of exceptions and trends, and corrective action with effectiveness evidence when performance fails. Tracers and staff interviews should agree with the written procedure.
CAP deficiencies and responses
CAP checklist requirements are assigned Phase I or Phase II ; the phase is attached to the cited checklist item, not improvised from an informal “minor versus serious” label. CAP requires a response to all deficiencies within 30 calendar days . A Phase I response describes corrective action. A Phase II response also supplies supporting documentation demonstrating compliance.
For either phase, define scope, correct immediate risk, identify causes, implement systemic action, and verify effectiveness. If patient results may be affected, conduct a documented look-back, decide whether reports require correction, and notify clinicians as required.
Tracer methodology
A tracer follows a patient, specimen, result, or process across handoffs. For a blood culture, it could examine the order, identifiers, collection antisepsis, transport, incubation, alerts, preliminary calls, susceptibility reporting, critical-result documentation, and stewardship follow-up. A tracer is valuable because a technically correct bench process can still fail at an interface.
Proficiency testing fundamentals
For CLIA-regulated analytes, laboratories enroll in a CMS-approved PT program. The usual design is three testing events per year with five challenges per regulated analyte per event , subject to current specialty rules. PT samples are tested like patient specimens by routine personnel using the routine method. Before the reporting deadline, the laboratory must not send PT material to another laboratory for testing or communicate results in a way that creates interlaboratory collaboration.
The laboratory director reviews PT results. For each unacceptable result, investigate transcription, specimen handling, reagent and calibration status, instrument function, peer-group assignment, calculations, and staff practice. Corrective action is documented even when the overall event remains satisfactory.
Unsatisfactory and unsuccessful performance
The precise scoring criteria and terminology are in 42 CFR Part 493 and current CMS guidance. A single unacceptable event may be unsatisfactory performance ; repeated failures meeting the regulatory pattern are unsuccessful performance . The manager must classify performance for the specific analyte or subspecialty and act promptly.
Older summaries often state that every initial unsuccessful PT finding automatically causes a six-month testing suspension. Current CMS enforcement guidance is more nuanced. CMS may direct training or technical assistance after an initial unsuccessful performance. Sanctions or directed cessation depend on facts such as immediate jeopardy, failure to correct, and compliance history. There is no single enforcement response for every laboratory and every initial event.
PT referral
PT referral is distinct from poor analytical performance. Intentional referral or interlaboratory communication can trigger severe statutory consequences, but current law and CMS guidance contain defined enforcement paths and possible alternative sanctions in specified circumstances. The operational rule is simple: keep PT inside the laboratory's ordinary patient-testing workflow, document who performed it, prohibit pre-deadline result sharing, and escalate suspected referral immediately.
Survey response workflow
When an accreditor or CMS identifies a deficiency: protect patients and stop unsafe testing if necessary; preserve records and define scope; perform a patient-result look-back when indicated; correct immediate problems; identify systemic causes; submit the response by the required deadline with required evidence; and monitor effectiveness until sustained compliance is demonstrated.